Topics

Deciphera’s GIST Treatment Earns Priority Review from FDA

19:00 EST 12 Feb 2020 | BioSpace

Steve Hoerter, president and chief executive officer of Deciphera, said the acceptance of the NDA brings the company one step closer to its goal of providing a new treatment option for patients with advanced GIST.

Original Article: Deciphera’s GIST Treatment Earns Priority Review from FDA

NEXT ARTICLE

More From BioPortfolio on "Deciphera’s GIST Treatment Earns Priority Review from FDA"

Quick Search